Übersetzung für "Living donor" in Deutsch

We can do a partial liver transplant from a living donor.

And what about organ donation with a living donor?

The living donor must not receive remuneration of any kind, other than compensation to cover inconveniences following the operation, to be determined by national regulations.

The Mikolášik report on safety and quality standards for organs intended for transplantation thus makes an important contribution towards minimising organ shortage and towards basic protection of the health of the recipient and the living donor.

The principle of non-payment does not apply to cases of so-called compensation, where a living donor may receive a contribution in line with the expenditure related to donation.

Donation should also be voluntary, and therefore requires obligatory informed and written consent by the living donor.

Patients at low to moderate immunological risk were studied in the phase 3 ciclosporin elimination-Rapamune maintenance study, which included patients receiving a renal allograft from a cadaveric or living donor.

In another Phase 3 study in recipients of living donor and standard criteria deceased donor kidneys (Study 1), the incidence of graft thrombosis was 2.3% and 0.4% for the MI and LI regimens respectively, versus 1.8% for ciclosporin.

In order to ensure that the health status of a living donor is not affected by the donation, a prior medical examination is required.

For the allogeneic living donor (AL), information must be provided to the donor on the evaluation procedure: i.e. the reasons for requiring the donor’s medical and personal history, a physical examination, and analytical tests.

The selection criteria for the allogeneic living donor shall be established and documented by the responsible physician based on the donor’s physical status, clinical and personal record, the results of clinical analyses, and other laboratory tests establishing the donor’s health.

This information, coupled with the exchange of best practices on living donation programmes among the Member States, should help to develop evidence-based guidelines and consensus documents, and address the selection, evaluation and follow-up of the living donor.

The potential living donor has to be able to take an independent decision on the basis of all the relevant information and should be informed in advance as to the purpose and nature of the donation, the consequences and risks.

If the removed cells or tissues are stored or cultured, the same serology tests must be carried out as for an allogeneic living donor.

If in a living donor (except allogeneic haematopoietic progenitor cell donors) the blood sample is drawn 6 days after procurement and tested by nucleic acid amplification technique (NAT), a repeat blood sample is not necessary for HIV, HBV and HCV.

In another phase 3 study in recipients of living donor and standard criteria deceased donor kidneys (Study 1), the incidence of graft thrombosis was 2.3% and 0.4% for the MI and LI regimens respectively, versus 1.8% for ciclosporin.